FLT3 and acute myeloid leukemia: This indicates that FLT3-mutated AML clones have a survival advantage during standard therapy, expanding to drive relapse unless effectively eradicated, but the efficacy of TKIs in eliminating FLT3-mutated clones remains variable35–37.